BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29333016)

  • 21. A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups.
    Gao Y; Wei L; Kim SJ; Wang L; He Y; Zheng Y; Bertero L; Pellerino A; Cassoni P; Tamagnone L; Theresa PK; Deutsch A; Zhan H; Lai J; Wang Y; You H
    Front Oncol; 2021; 11():696147. PubMed ID: 34422649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of additional radiotherapy for primary central nervous system lymphoma.
    Zacher J; Kasenda B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma.
    Ouyang T; Wang L; Zhang N; Zhang Z; Xiong Y; Li M; Hong T
    World Neurosurg; 2020 Jul; 139():e508-e516. PubMed ID: 32311566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
    Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
    Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis.
    Kaulen LD; Karschnia P; Dietrich J; Baehring JM
    J Neurooncol; 2020 Aug; 149(1):153-159. PubMed ID: 32683530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
    Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
    Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.
    Wu S; Wang J; Liu W; Hu F; Zhao K; Jiang W; Lei T; Shu K
    BMC Neurol; 2021 May; 21(1):190. PubMed ID: 33975554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic Factors of the Primary Central Nervous System Lymphoma: Clinical Experience from a Tertiary Care Center in the Middle East.
    Ebrahimi H; Esfandbod M; Ketabchi SM; Yarandi KK; Shirani M; Amirjamshidi A; Alimohamadi M
    Asian J Neurosurg; 2023 Mar; 18(1):36-39. PubMed ID: 37056898
    [No Abstract]   [Full Text] [Related]  

  • 33. Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
    Zeremski V; Adolph L; Beer S; Berisha M; Jacobs B; Kahl C; Koenecke C; Kropf S; Panse J; Petersen J; Schmidt-Hieber M; Schneider J; Vucinic V; Walter J; Weigert O; Witte HM; Mougiakakos D
    Eur J Haematol; 2024 Apr; 112(4):641-649. PubMed ID: 38164819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
    Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
    J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).
    Gomes Candido Reis D; Levy D; Lage LAPC; Culler HF; Rocha V; Bydlowski SP; Nogueira Zerbini MC; Pereira J
    Brain Behav; 2021 Apr; 11(4):e02061. PubMed ID: 33591648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
    Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
    Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary Central Nervous System Lymphoma, Treatment Outcomes - 10 Year Experience. Single Center Study.
    Nizic A; Ibricevic-Balic L; Ceric T; Omerhodzic I; Burazerovic L; Saric V; Mameledzija E; Hasanefendic B
    Mater Sociomed; 2024; 36(1):23-25. PubMed ID: 38590596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
    Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
    Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.